Research and development are vital components of the overall value chain and essential to our company.
We invest heavily in basic and applied research and are prioritizing our efforts in the core therapeutic areas that we feel offer the most potential for us scientifically and commercially.
A leader in the field of complex generic medicines, Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of autoimmune/neurodegenerative diseases – particularly multiple sclerosis - and oncology. The vertically integrated model we developed for high quality small molecule generics has been extended to our newer technological platforms of biosimilars, new biological and new chemical entities.
Analytical and clinical research
In addition to chemical and (bio)pharmaceutical R&D, we carry out analytical and clinical research at our locations worldwide. We have our own fully functional clinical drug development unit and intend to take our development phase compounds into clinical trials - up to Phase III.
The combination of innovative R&D and proven ability to manufacture and distribute high quality pharmaceuticals positions us well for our future in specialty pharmaceuticals.